Cargando…

High‐throughput sequencing detection and ensartinib treatment of lung cancer harboring NTRK1 fusion

Detalles Bibliográficos
Autores principales:	Song, Zhengbo, Xu, Chunwei, Pu, Xingxiang, Zhu, Youcai, Wang, Wenxian, Li, Xingliang, Gao, Yanqiu, Zhu, Wenliang, He, Yunwei, Wu, Lin, Mao, Li, Chen, Li, Chen, Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896745/ https://www.ncbi.nlm.nih.gov/pubmed/33452864 http://dx.doi.org/10.1002/cac2.12133

Ejemplares similares

ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib
por: Xu, Shuguang, et al.
Publicado: (2019)

Molecular and clinicopathologic features of gliomas harboring NTRK fusions
por: Torre, Matthew, et al.
Publicado: (2020)

Case Report: Ensartinib for gastric epithelioid inflammatory myofibrosarcoma with STRN-ALK fusion
por: Li, XiaoQing, et al.
Publicado: (2023)

Genomic Evolution and Personalized Therapy of an Infantile Fibrosarcoma Harboring an NTRK Oncogenic Fusion
por: Thorwarth, Anne, et al.
Publicado: (2022)

Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China
por: Xu, Chunwei, et al.
Publicado: (2022)

Genomic Features of Solid Tumor Patients Harboring ALK/ROS1/NTRK Gene Fusions
por: Dai, Yinghuan, et al.
Publicado: (2022)

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence
por: Ricciuti, Biagio, et al.
Publicado: (2019)

Durable Clinical Response to Larotrectinib in an Adolescent Patient With an Undifferentiated Sarcoma Harboring an STRN-NTRK2 Fusion
por: Wu, Lawrence W., et al.
Publicado: (2018)

Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1
por: Hemming, Matthew L., et al.
Publicado: (2020)

Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC
por: Peng, Ling, et al.
Publicado: (2021)

FGFR2-BICC1: A Subtype Of FGFR2 Oncogenic Fusion Variant In Cholangiocarcinoma And The Response To Sorafenib
por: Ying, Xihui, et al.
Publicado: (2019)

Refractory and metastatic infantile fibrosarcoma harboring LMNA–NTRK1 fusion shows complete and durable response to crizotinib
por: Bender, Jonathan, et al.
Publicado: (2019)

Antitumor Activity of Larotrectinib in Tumors Harboring NTRK Gene Fusions: A Short Review on the Current Evidence [Corrigendum]
Publicado: (2020)

Entrectinib use in a platinum-refractory mucinous ovarian cancer harboring a NTRK3 gene fusion
por: Beck, Olivia G., et al.
Publicado: (2023)

STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report
por: Zhang, Linlin, et al.
Publicado: (2022)

NTRK1 Fusion in Glioblastoma Multiforme
por: Kim, Jinkuk, et al.
Publicado: (2014)

Identifying patients with NTRK fusion cancer
por: Solomon, J P, et al.
Publicado: (2019)

NTRK fusion in Japanese colorectal adenocarcinomas
por: Yamashiro, Yuya, et al.
Publicado: (2021)

A review of NTRK fusions in cancer
por: Manea, Cristina Alexandra, et al.
Publicado: (2022)

Case report: Epithelioid inflammatory myofibroblastic sarcoma treated with an ALK TKI ensartinib
por: Li, Mengmeng, et al.
Publicado: (2023)

P-glycoprotein Mediates Resistance to the Anaplastic Lymphoma Kinase Inhiitor Ensartinib in Cancer Cells
por: Wu, Chung-Pu, et al.
Publicado: (2022)

Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion
por: Pitoia, Fabián
Publicado: (2021)

Case Report: Efficacy of ensartinib treatment in pulmonary inflammatory myofibroblastic tumor with a rare GCC2-ALK fusion
por: He, Wenguang, et al.
Publicado: (2022)

Correction: NTRK1 Fusion in Glioblastoma Multiforme
Publicado: (2014)

NTRK fusions are extremely rare in bone tumours
por: Lam, Suk Wai, et al.
Publicado: (2021)

Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population
por: Zhao, Ruiying, et al.
Publicado: (2021)

Case Report: Identification of a novel NTRK3-AJUBA fusion co-existing with ETV6-NTRK3 fusion in papillary thyroid carcinoma
por: Yu, Qing-Xiang, et al.
Publicado: (2023)

EPEN-25. EXCEPTIONAL CLINICAL AND IMAGING RESPONSE TO TRK-INHIBITION IN A PATIENT WITH SUPRATENTORIAL EPENDYMOMA HARBORING NTRK2 GENE FUSION
por: Mangum, Ross, et al.
Publicado: (2020)

Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions
por: Brčić, Iva, et al.
Publicado: (2020)

A non-functional 5′ ALK fusion validated at the RNA level as a classical EML4-ALK that responds well to the novel ALK inhibitor ensartinib: A case report
por: Yang, Hong, et al.
Publicado: (2022)

NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome
por: Zhao, Xiaonan, et al.
Publicado: (2021)

Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor
por: Wang, Wenxian, et al.
Publicado: (2016)

Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements
por: Zhang, Yongchang, et al.
Publicado: (2022)

Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors
por: Kang, Jeongwan, et al.
Publicado: (2020)

NTRK fusions in osteosarcoma are rare and non‐functional events
por: Ameline, Baptiste, et al.
Publicado: (2020)

NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects
por: Siozopoulou, Vasiliki, et al.
Publicado: (2021)

NTRK Gene Fusion Detection in Atypical Spitz Tumors
por: Cappellesso, Rocco, et al.
Publicado: (2021)

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors
por: Konicek, Bruce W., et al.
Publicado: (2018)

A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: a case report
por: Zhou, Ning, et al.
Publicado: (2018)

Mixed response and mechanisms of resistance to larotrectinib in metastatic carcinoma ex pleomorphic adenoma of the parotid harboring an NTRK2 fusion: A case report
por: Pircher, Magdalena, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vea64pe8do0m86uuh73h8bpvet